<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04405557</url>
  </required_header>
  <id_info>
    <org_study_id>PREDICT</org_study_id>
    <nct_id>NCT04405557</nct_id>
  </id_info>
  <brief_title>The PREDICT Study: Prospective Early Detection In a Population at High-risk for Common Malignant Tumor</brief_title>
  <official_title>Study on the Application of ctDNA in a Population at High-risk for Common Malignant Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geneplus-Beijing Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Geneplus-Beijing Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a observational, multicenter study, monitoring the circulating tumor DNA (ctDNA) in
      people who is at risk of cancers，assessing the sensitivity and specificity of ctDNA detection
      in early screening of pan-carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2000 patients with positive tumor protein markers or cancer screening were recruited. All
      patients were tested for ctDNA at enrollment and followed up at 6 months and 1 year. The
      study was completed at the time of cancer diagnosis or the longest follow-up time (1 year).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2019</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of ctDNA for early detection in cancer high-risk population.</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the sensitivity, specificity and positive predictive value of ctDNA for screening in high-risk population. Including the following six types of cancer: hepatocellular carcinoma, pancreatic cancer, ovarian cancer, breast cancer, colorectal cancer and gastric cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Window period from ctDNA positive to cancer diagnosis.</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the time from ctDNA positive to cancer diagnosis for patients diagnosed with cancer during the trial period.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Early Detection of Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        People with positive tumor protein marker or cancer screening.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged at or over 45 years old.

          2. Patients who with one or more of the following situations:

               1. In AFP (&gt;20UG/L), CA125 (&gt;70U/ml), CEA (&gt;7ng/ml) and CA199 (&gt;60U/ml), more than
                  one item was abnormal for two consecutive times within one month.

               2. Patients with viral hepatitis (Hepatitis B / C surface antigen positive with
                  liver function damage.

               3. Patients with liver nodules detected by ultrasound and hemangioma excluded.

               4. Patients with compensated cirrhosis.

               5. CA125&gt;35U/ml and HE4 was abnormal (the reference value of HE4 in premenopausal
                  and postmenopausal women was 68.96 pmol/L and 114.90 pmol/L respectively).

               6. Patients with ovarian masses found by ultrasonography (premenopausal &gt; 5cm,
                  postmenopausal &gt; 3.5cm).

               7. Patients with pancreatic space-occupying found by ultrasonography.

               8. Patients with BI-RADS grade 4 or above by ultrasound or mammography.

               9. CA125&gt;35U/ml and BI-RADS above grade 3 by ultrasound or mammography.

              10. CA153&gt;25U/ml and BI-RADS above grade 3 by ultrasound or mammography.

              11. Family genetic history of breast cancer and ovarian cancer, and BI-RADS above
                  grade 3 by ultrasound or mammography.

              12. Patients with a positive fecal occult blood test and haemorrhoids excluded

              13. Patients with a positive fecal occult blood test and positive CEA

              14. More than 2 items were abnormal in PGI, PGR and G-17 (criteria: PGI≤70 UG/L,
                  PGR≤7.0, G-17≤1 pmol/L or G-17≥15 pmol/L).

          3. Ability to collect specimens from each time point and provide corresponding clinical
             information.

          4. Understand the research plan and voluntarily participate in the study, sign the
             informed consent form.

        Exclusion Criteria:

          1. Patients with previous or present cancer.

          2. Patients with serious diseases, especially those with a survival period of less than 3
             years.

          3. Patients with factors that affect the diagnosis of the disease (such as MRI related
             cardiac pacemakers, ferromagnetic implants, etc.).

          4. Patients with a known history of allogeneic organ transplantation or allogeneic
             hematopoietic stem cell transplantation.

          5. Women who are pregnant or preparing for pregnancy.

          6. Patients who voluntarily withdraw for any reason.

          7. Patients who cannot complete the research plan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiang Zeng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qiang Zeng, MD</last_name>
    <phone>13911736252</phone>
    <email>ZQ301@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Zeng, MD</last_name>
      <phone>13911736252</phone>
      <email>ZQ301@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiqing Wu, MB</last_name>
      <phone>13802258083</phone>
      <email>wweiqing007@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongli Li, MD</last_name>
      <phone>13633812936</phone>
      <email>shyliyongli@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaohui Liu, MB</last_name>
      <phone>13337313360</phone>
      <email>shaohui_liu@msn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qun Zhang, MD</last_name>
      <phone>13805182208</phone>
      <email>jszhangqun@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>China-Japan Union Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130033</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongjun Li, MD</last_name>
      <phone>13844075818</phone>
      <email>lihongjun@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Jinzhou Medical University</name>
      <address>
        <city>Jinzhou</city>
        <state>Liaoning</state>
        <zip>121001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhitu Zhu, MD</last_name>
      <phone>13897872139</phone>
      <email>ZHUZHITU@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sichuan Provincial People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuping Liu, MM</last_name>
      <phone>18981838972</phone>
      <email>liuyuping555@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 9, 2020</study_first_submitted>
  <study_first_submitted_qc>May 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pan-cancer</keyword>
  <keyword>cancer screening</keyword>
  <keyword>ctDNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

